Metastatic Liver Cancer Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Others

(Albany, United States), DelveInsight's "Metastatic-Liver-Cancer Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the pipeline drug profiles, including Metastatic Liver Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Metastatic Liver Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Metastatic Liver Cancer clinical trials studies, Metastatic Liver Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic-Liver-Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

To explore more information on the latest breakthroughs in the Metastatic Liver Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/report-store/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Metastatic Liver Cancer Pipeline Report
• DelveInsight's Metastatic Liver Cancer Pipeline analysis depicts a robust space with 20+ active players working to develop 25+ pipeline treatment therapies.
• The leading Metastatic-Liver-Cancer Companies includes Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Promising Metastatic-Liver-Cancer Pipeline Therapies includes Adecatumumab, FOLFOX 4, EMD 525797, AV-299, AZD2171, Talimogene Laherparepvec, Atezolizumab, STP705, and others.
• On March 2022, AllVascular has announced drug named Intra-arterial LIOX + Capecitabine in the market by the phase 1 & 2. The treatment proposed in this trial is to administer intra-arterial chemotherapy to liver metastases from colorectal cancer when the blood flow to and from the liver has been isolated via balloon catheters through a vascular access system called the AVAS. The objective of this study is to evaluate the tumour response of repeated and isolated intra-arterial liver isolation oxaliplatin compared with the standard systemic chemotherapy (intravenous 5-FU + leucovorin + oxaliplatin [FOLFOX] or oral capecitabine with IV oxaliplatin [XELOX]).
• On November 2022, Amgen has announced drug named Talimogene Laherparepvec and Atezolizumab in the market by the phase 1. Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland. The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases.

Metastatic Liver Cancer Overview
The liver is a common site for metastases from many cancer types. Cancers that spread to the liver most often are colorectal cancer as well as with breast, esophageal, stomach, pancreatic, lung, kidney and melanoma skin cancers. Cancers spread to the liver because the liver filters most of the blood from the rest of the body, and when cancer cells break away from a primary cancer, they often enter and travel through the bloodstream.

For further information, refer to the detailed Metastatic Liver Cancer Unmet Needs, click here for Metastatic Liver Cancer Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Liver Cancer Emerging Drugs Profile
• exoASO STAT6: Codiak BioSciences
• STP 705: Sirnaomics
• ONCR 177: Oncorus

Metastatic Liver Cancer Pipeline Therapeutics Assessment
There are approx. 20+ Metastatic Liver Cancer companies which are developing the therapies for Metastatic-Liver-Cancer. The Metastatic Liver Cancer companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.

Request a sample and discover the recent advances in Metastatic Liver Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Liver Cancer Drugs and Companies
• Adecatumumab: Amgen Research (Munich) GmbH
• AZD2171: AstraZeneca
• Lipiodol: Guerbet
• DCE MRI: Bracco Diagnostics Inc

Metastatic Liver Cancer Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Metastatic Liver Cancer Therapeutics Market include-
Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.

Dive deep into rich insights for drugs for Metastatic Liver Cancer Pipeline, click here for Metastatic Liver Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Liver Cancer Pipeline Report
• Coverage- Global
• Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Metastatic Liver Cancer Therapies- Adecatumumab, FOLFOX 4, EMD 525797, AV-299, AZD2171, Talimogene Laherparepvec, Atezolizumab, STP705, and others.
• Metastatic Liver Cancer Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Metastatic Liver Cancer Pipeline, click here for Metastatic Liver Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Metastatic-Liver-Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic-Liver-Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ONCR 177: Oncorus
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic-Liver-Cancer Key Companies
21. Metastatic-Liver-Cancer Key Products
22. Metastatic-Liver-Cancer- Unmet Needs
23. Metastatic-Liver-Cancer- Market Drivers and Barriers
24. Metastatic-Liver-Cancer- Future Perspectives and Conclusion
25. Metastatic-Liver-Cancer Analyst Views
26. Metastatic-Liver-Cancer Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/market-&-competitive-assessment

This release was published on openPR.